Isaac Barchas Sells 10,125 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 10,125 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $26.07, for a total value of $263,958.75. Following the transaction, the director owned 62,291 shares in the company, valued at approximately $1,623,926.37. This trade represents a 13.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total value of $301,058.00.
• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Performance

NASDAQ:IMNM opened at $26.42 on Friday. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $28.62. The firm’s 50-day simple moving average is $22.02 and its 200 day simple moving average is $22.20. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of -10.44 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Sell-side analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current year.

Institutional Trading of Immunome

Several large investors have recently made changes to their positions in IMNM. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. BlackRock Inc. bought a new stake in Immunome during the second quarter worth $186,588,000. Vanguard Group Inc. lifted its stake in Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA boosted its holdings in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a Buy rating. The new target implies substantial potential upside and helped support investor interest in IMNM, which reached a fresh 52-week high following the upgrade. Truist price target update
• Positive Sentiment: An investment thesis highlighted two potential catalysts: FDA acceptance of varegacestat’s new drug application and a PDUFA decision date in April 2027. Investors are also watching IM-1021, Immunome’s Phase 1 ROR1 antibody-drug conjugate, with initial data expected in 2026. The company believes its proprietary TOP1 inhibitor payload could offer advantages in efficacy, resistance management and bystander effects. Immunome catalysts and pipeline analysis
• Positive Sentiment: Immunome’s second-quarter business update kept attention focused on its antibody-based oncology and infectious-disease pipeline, which remains the primary driver of the company’s valuation and future growth prospects. Immunome second-quarter 2026 results
• Neutral Sentiment: Director Isaac Barchas sold shares in several transactions from August 10 through August 12, including approximately 98,712 shares for about $2.6 million. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of current management sentiment, although they may add short-term supply pressure. Immunome director sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the expected loss of $0.51. The earnings miss underscores the company’s ongoing cash-burn and execution risks while its pipeline remains in development.

Analyst Ratings Changes

A number of brokerages recently issued reports on IMNM. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Leerink Partners cut their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, HC Wainwright restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.